HANDOK Inc. (KRX:002390)
South Korea · Delayed Price · Currency is KRW 9,460.00
0.00 (0.00%)
Sep 11, 2026, 3:30 PM KST
HANDOK Revenue
HANDOK had revenue of 140.73B KRW in the quarter ending June 30, 2026, with 7.81% growth. This brings the company's revenue in the last twelve months to 560.89B, up 12.01% year-over-year. In the year 2025, HANDOK had annual revenue of 535.14B with 5.48% growth.
Revenue (ttm)
560.89B
Revenue Growth
+12.01%
P/S Ratio
0.22
Revenue / Employee
616.36M
Employees
910
Market Cap
122.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 535.14B | 27.78B | 5.48% |
| Dec 31, 2024 | 507.36B | -15.38B | -2.94% |
| Dec 31, 2023 | 522.74B | -21.02B | -3.87% |
| Dec 31, 2022 | 543.76B | 26.12B | 5.05% |
| Dec 31, 2021 | 517.64B | 14.03B | 2.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharma Holdings | 630.89B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Dongwha Pharm.Co.,Ltd | 513.24B |
| Kyongbo Pharmaceutical | 279.55B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| Daihan Pharmaceutical | 216.55B |
| Samil Pharmaceutical Co.,Ltd | 207.33B |
| Hana Pharm | 139.33B |